Partial remission in patients newly diagnosed with type 1 diabetes is a period of good glucose control that can last from several weeks to over a year. The clinical significance of the remission period is that patients might be more responsive to immunotherapy if treated within this period. This article provides clinical data that indicates the level of glucose control and insulin-secreting β-cell function of each patient in the study at baseline (within 3 months of diagnosis), and at 3, 6, 9, 12, 18 and 24 months post-baseline. The relative frequency of immune cell subsets in the PBMC of each patient and the association between the frequency of immune cell subsets measured and length of remission is also shown. These data support the findi...
OBJECTIVE: To evaluate whether indexes of glycemic variability may overcome residual β-cell secretio...
This is the author accepted manuscript. The final version is available from the American Association...
P rogressive loss of -cell mass in type1 diabetes results from CD4 andCD8 T-cell autoimmunity targ...
AbstractPartial remission in patients newly diagnosed with type 1 diabetes is a period of good gluco...
Transient partial remission, a period of low insulin requirement experienced by most patients soon a...
Objective: Type 1 diabetes (T1D) develops in distinct stages, before and after disease onset. Whethe...
Type 1 diabetes is characterized by autoimmurte destruction of pancreatic beta-cells in genetically ...
Type 1 diabetes is characterized by autoimmune destruction of pancreatic β-cells in genetically susc...
Abstract: Type 1 diabetes is caused by autoreactive T cells that destroy pancreatic beta cells. Anim...
Type 1 diabetes is a chronic autoimmune disease mediated by autoreactive T-cells. Several experiment...
We read with interest the article recently pub-lished by Greenbaum et al. (1) describing thenovel ob...
Published onlineJOURNAL ARTICLEAIMS/HYPOTHESIS: This study aimed to determine the frequency of resid...
OBJECTIVE: To identify predictors of residual beta-cell function and glycemic control during the fir...
The hypothesis was tested that the systemic immune milieu in recent-onset type 1 diabetes is associa...
<p><b>A</b>. Correlation of log(%MAIT cells of total CD8 T cells) versus age in years among controls...
OBJECTIVE: To evaluate whether indexes of glycemic variability may overcome residual β-cell secretio...
This is the author accepted manuscript. The final version is available from the American Association...
P rogressive loss of -cell mass in type1 diabetes results from CD4 andCD8 T-cell autoimmunity targ...
AbstractPartial remission in patients newly diagnosed with type 1 diabetes is a period of good gluco...
Transient partial remission, a period of low insulin requirement experienced by most patients soon a...
Objective: Type 1 diabetes (T1D) develops in distinct stages, before and after disease onset. Whethe...
Type 1 diabetes is characterized by autoimmurte destruction of pancreatic beta-cells in genetically ...
Type 1 diabetes is characterized by autoimmune destruction of pancreatic β-cells in genetically susc...
Abstract: Type 1 diabetes is caused by autoreactive T cells that destroy pancreatic beta cells. Anim...
Type 1 diabetes is a chronic autoimmune disease mediated by autoreactive T-cells. Several experiment...
We read with interest the article recently pub-lished by Greenbaum et al. (1) describing thenovel ob...
Published onlineJOURNAL ARTICLEAIMS/HYPOTHESIS: This study aimed to determine the frequency of resid...
OBJECTIVE: To identify predictors of residual beta-cell function and glycemic control during the fir...
The hypothesis was tested that the systemic immune milieu in recent-onset type 1 diabetes is associa...
<p><b>A</b>. Correlation of log(%MAIT cells of total CD8 T cells) versus age in years among controls...
OBJECTIVE: To evaluate whether indexes of glycemic variability may overcome residual β-cell secretio...
This is the author accepted manuscript. The final version is available from the American Association...
P rogressive loss of -cell mass in type1 diabetes results from CD4 andCD8 T-cell autoimmunity targ...